[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-carcinosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-carcinosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629727","impact-of-an-omega-3-enriched-oral-nutritional-supplement-on-improving-surgical-outcomes-in-patients-with-peritoneal-carcinomatosis-undergoing-cytoreductive-surgery-100629727",false,"NCT07478432","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery: A Pilot, Prospective, Randomized, Double-Blind, Controlled Study","OMNI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of peritoneal carcinomatosis from a non-gynecological primary neoplasm\n* Patients who must undergo cytoreductive surgery and HIPEC\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patients with an enterocutaneous fistula\n* Patients with known food allergies\n* Age \\\u003C 18 years\n* Patients with severe organ damage (e.g., kidney failure, liver failure)\n* Refusal to sign the informed consent form","ALL","18 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OMNI study is a clinical trial investigating whether a nutritional supplement with added Omega-3 fatty acids can improve surgical outcomes for patients with peritoneal carcinomatosis. Peritoneal carcinomatosis is a type of cancer that affects the abdominal lining and often requires complex and extensive surgery called cytoreductive surgery (CRS). This procedure is associated with a high risk of postoperative complications, such as infections and long hospital stays. Omega-3 fatty acids are known for their anti-inflammatory and immune-modulating properties.\n\nThe study's main goal is to see if a 21-day regimen of a pre-operative Omega-3 enriched oral nutritional supplement (ONS) can reduce postoperative complications, as measured by the Clavien-Dindo classification.\n\nWho can participate?\n\nThe study is recruiting patients over 18 years old who have been diagnosed with non-gynecological peritoneal carcinomatosis and are scheduled to undergo cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy).\n\nWhat does participating involve?\n\nUpon joining the study, participants will be randomly assigned to one of two groups:\n\n* Intervention Group: Participants will receive an Omega-3 enriched nutritional supplement called Fortimel Forticare.\n* Control Group: Participants will receive a standard nutritional supplement called Fortimel Compact Protein.\n\nBoth groups will be asked to consume two bottles of their assigned supplement per day for 21 days before the scheduled surgery.\n\nWhat will be measured?\n\nThroughout the study, the investigators will perform various assessments to monitor participant health and recovery:\n\n* Before and after surgery: The investigators will take body measurements, conduct a bioimpedance analysis (BIA) to check body composition, and perform a Hand Grip test to measure muscle strength. The investigators will also collect blood and stool samples.\n* During surgery: The investigators will collect tissue samples to study the tumor environment.\n* After surgery: The investigators will track patient recovery, including the length of the hospital stay and any complications that may occur. The investigators will also continue to monitor certain markers in the patients' blood.\n\nThe study is expected to enroll a total of 28 patients.",[27,28,29,30],"Peritoneal Carcinosis","Peritoneal Metastases","HIPEC","Cytoreductive Surgery","NOT_YET_RECRUITING","2026-03-13",{"date":34,"type":35},"2026-03-17","ACTUAL",{"date":37,"type":21},"2026-04",{"date":39,"type":21},"2028-10",{"name":41,"class":42},"Catholic University of the Sacred Heart","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100613847","ponder-pelvic-peritonectomy-in-early-stage-ovarian-tumors-100613847","NCT07271914","PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors","Pelvic peritOnectomy iN Early Stage Ovarian Tumors: a prospEctive Study","PONDER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* FIGO 2018 stage IA-IB epithelial or non-epithelial ovarian or fallopian tube tumors\n* Complete preoperative work-up (ultrasound, CT scan, tumor markers)\n* Laparoscopic, robotic or open surgical approach\n* Signed informed consent\n\nExclusion Criteria:\n\n* Sarcomas, melanomas, mesotheliomas, hematologic malignancies\n* Advanced ovarian tumors\n* Fertility-sparing surgery with uterine preservation\n* Inability to provide informed consent","FEMALE",{"count":54,"type":21},390,[24],"Early-stage ovarian tumors represent approximately 30% of all newly diagnosed ovarian cancers. Current international guidelines recommend random peritoneal biopsies for surgical staging, but the diagnostic yield of these biopsies remains limited. The PONDER study aims to evaluate whether standardized surgical procedure and pathology assessment of wider peritoneal pelvic biopsies can increase the detection rate of microscopic peritoneal implants and micrometastases in patients with early-stage ovarian tumors. This multicenter, prospective, single-arm study includes both minimally invasive and open surgical approaches, with a standardized gross and microscopic evaluation of the resected peritoneal specimens",[58,27],"Early Stage Ovarian Tumors",[60,61,62,63,64],"ovarian cancer","early stage","ovarian tumor","peritoneal carcinosis","pathology assessment","2025-11-26",{"date":67,"type":35},"2025-12-09",{"date":69,"type":21},"2026-02",{"date":71,"type":21},"2032-08",{"name":73,"class":42},"Ospedale Santa Croce-Carle Cuneo",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100379506","development-of-a-clinical-and-biological-database-in-peritoneal-carcinosis-bcb-carcinose-100379506","NCT04221464","Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)","Development of a Clinical and Biological Database Monocentric and Prospective in Peritoneal Carcinosis","BCB","Inclusion Criteria:\n\n* Patient over the age of 18;\n* Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer\n* Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease\n* Patient agree will all study procedure : biological samples \\& tissues samples\n* Patient giving informed consent\n\nExclusion Criteria:\n\n* Patient not affiliated to Social Protection system\n* Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons\n* The level of French is insufficient to consent to the study and to response to the questionnaires\n* Patient under guardianship\n* Pregnancy ou breast-feeding women\n* Patient treated in case of an emergency",{"count":83,"type":21},600,[24],"The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.",[87,27],"Cancer","RECRUITING","2025-02-11",{"date":91,"type":35},"2025-02-12",{"date":93,"type":35},"2019-11-25",{"date":95,"type":21},"2038-02",{"name":97,"class":42},"Institut du Cancer de Montpellier - Val d'Aurelle"]